Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
News Editor's pick

Scholar Rock CEO says ISEMBYLD demand is steady as payer steps push most first infusions into 2027, at Jefferies London

Scholar Rock chief executive David Hallal told the Jefferies Global Healthcare Conference in London that weekly enrollment for its SMA drug ISEMBYLD has been steady since its September approval, but that most patients enrolled so far are likely to start treatment in early 2027.

Micrograph of pink-stained skeletal muscle fibers with dark nuclei, with the Scholar Rock logo on a white card
Skeletal muscle fibers under a light microscope (file photo). Scholar Rock's David Hallal spoke at the Jefferies Global Healthcare Conference in London on November 17, 2026. Photo: “Muscle Tissue: Skeletal Muscle Fibers”, Berkshire Community College Bioscience Image Library, via Wikimedia Commons, CC0; cropped, Scholar Rock logo added by Onyx.
Table of Contents

Scholar Rock used a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 to describe steady weekly demand for its spinal muscular atrophy (SMA) drug ISEMBYLD (apitegromab-mstn) in the first weeks of its U.S. launch, while warning that most patients enrolled so far are likely to receive a first infusion in early 2027 rather than this year. Chairman and chief executive officer David Hallal spoke with Phoebe Tan of Jefferies.

A muscle-targeted SMA drug

The FDA approved ISEMBYLD on September 11 for adults and children two years of age and older with SMA who are receiving a survival motor neuron 2 (SMN2)-targeted treatment. The antibody blocks activation of myostatin, a protein that limits muscle growth, and is infused every four weeks.

Hallal said the approval came “after 20 years of failed clinical development across a wide range of biopharma companies” working on myostatin. “Muscle is the principal organ clinically affected by SMA,” Hallal said.

Early demand

Scholar Rock has reported that more than a third of the top 140 U.S. SMA treatment centers enrolled patients in its Scholar Rock Supports program in the first six weeks of launch. Hallal said more of the new enrollment forms came from patients who had never received ISEMBYLD than from patients already on it through the company’s expanded access program or its long-term extension trial.

Hallal said enrollments are balanced across U.S. regions and that “we’re seeing all types of disease trajectories”, from improving to declining motor function. “We haven’t seen any peaks and valleys of demand,” Hallal said. Scholar Rock estimates that about 6,600 U.S. patients are receiving an SMN2-targeted therapy.

Why infusions lag demand

Scholar Rock has said prescription to first infusion can take more than 60 to 90 days at launch. Hallal said ISEMBYLD has only a miscellaneous billing code until its own J-code takes effect on April 1, 2027, and that some insurers take three to six months or more to publish a policy. Anthem and Centene, which together cover 47 million lives, have published policies in line with the label, according to the company.

Hallal said time to treatment should fall to about two to three weeks within a year of approval, and that the company expects 85% of enrolled patients to go on to receive the drug. “It’s a very motivated patient population,” Hallal said. “They know it is a matter of when and not if they will be reimbursed.”

Hallal said about 240 U.S. patients now receive ISEMBYLD through the expanded access program or the extension trial, all expected to enroll in Scholar Rock Supports this quarter. Of patients from earlier trials who rolled into the extension study, 93% remain on therapy, some after seven years of infusions, Hallal said.

Price

Hallal put the wholesale acquisition cost at $11,659 per vial. Hallal said a typical patient of about 35 to 45 kilograms receives about three vials per infusion, 13 times a year, giving “a gross price in, say, a $450,000 range”. Scholar Rock has estimated the annual net price for a typical patient at about $310,000 after patient compliance, payer rebates and discounts.

Europe and Japan

Scholar Rock’s resubmitted application to the European Medicines Agency has been validated, and the company expects a CHMP opinion in the first half of 2027, with a first launch in Germany. Its Japanese application was accepted under priority review, for which Japan’s regulator has typically targeted about nine months.

Scholar Rock has said more than 35,000 SMA patients worldwide receive an SMN-targeted therapy. Hallal said those drugs generate more than $5 billion a year, with 64% of revenue outside the U.S.

Pipeline

Scholar Rock plans to share Phase 1 healthy volunteer data for SRK-439, a subcutaneous myostatin inhibitor, in early 2027, and is engaging regulators on a high-concentration subcutaneous form of apitegromab. A Phase 2 trial in facioscapulohumeral muscular dystrophy (FSHD), called FORGE, has begun dosing participants.

About Scholar Rock

Scholar Rock Holding Corporation (Nasdaq: SRRK) develops muscle-targeted treatments for SMA and other rare neuromuscular diseases. It plans to expand access to apitegromab to up to 50 countries.

Onyx has previously reported on last year’s Jefferies conference.


Sources: Scholar Rock fireside chat, Jefferies Global Healthcare Conference, London, November 17, 2026; Scholar Rock FDA approval announcement (September 11, 2026); Scholar Rock third quarter 2026 results and earnings call (November 10, 2026); Scholar Rock global regulatory update (August 21, 2026); Reuters and MedCity News on ISEMBYLD pricing (September 14, 2026)

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments

More News ↗